Impact of objective response and overall survival in patients with inoperable or metastatic gastric and esophagogastric junction (EGJ) cancer: Landmark analysis of 10 year data from first-line clinical trials

被引：0
|
作者：
Bolt, T. A. [1 ]
Pauligk, C. [1 ]
Werner, D. [1 ]
Mayer, F. [2 ]
Hofheinz, R. [3 ]
Nils, H. [4 ]
Luley, K. [5 ]
Schmalenberg, H. [6 ]
Egger, M. [7 ]
Al-Batran, S-E. [1 ]
机构：
[1] Krankenhaus Norwest, Inst Klin Onkol Forsch, Frankfurt, Germany
[2] Univ Med Ctr, Tubingen, Germany
[3] Univ Med Ctr, Dept Hematol & Med Oncol, Mannheim, Germany
[4] Klinikum Wolfsburg, Wolfsburg, Germany
[5] Univ Klinikum Lubeck, Lubeck, Germany
[6] Univ Tumorctr Jena, Jena, Germany
[7] Ortenau Klinikum, Lahr Ettenheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [41] Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
    Hutson, T. E.
    Al-Shukri, S.
    Stus, V. P.
    Lipatov, O. N.
    Shparyk, Y.
    Bair, A. H.
    Rosbrook, B.
    Andrews, G. I.
    Vogelzang, N. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S476 - S477
  • [42] Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients
    Vincenzo Catalano
    Francesca Bergamo
    Chiara Cremolini
    Bruno Vincenzi
    Francesca Negri
    Paolo Giordani
    Paolo Alessandroni
    Rossana Intini
    Silvia Stragliotto
    Daniele Rossini
    Beatrice Borelli
    Daniele Santini
    Donatella Sarti
    Marco B. L. Rocchi
    Sara Lonardi
    Alfredo Falcone
    Vittorina Zagonel
    Rodolfo Mattioli
    Francesco Graziano
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 493 - 501
  • [43] Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients
    Catalano, Vincenzo
    Bergamo, Francesca
    Cremolini, Chiara
    Vincenzi, Bruno
    Negri, Francesca
    Giordani, Paolo
    Alessandroni, Paolo
    Intini, Rossana
    Stragliotto, Silvia
    Rossini, Daniele
    Borelli, Beatrice
    Santini, Daniele
    Sarti, Donatella
    Rocchi, Marco B. L.
    Lonardi, Sara
    Falcone, Alfredo
    Zagonel, Vittorina
    Mattioli, Rodolfo
    Graziano, Francesco
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 493 - 501
  • [44] Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
    Masayuki Aboshi
    Masayuki Kaneko
    Mamoru Narukawa
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 839 - 848
  • [45] Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
    Aboshi, Masayuki
    Kaneko, Masayuki
    Narukawa, Mamoru
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (05) : 839 - 848
  • [46] Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
    Riccardo Giampieri
    Elena Maccaroni
    Alessandra Mandolesi
    Michela Del Prete
    Kalliopi Andrikou
    Luca Faloppi
    Alessandro Bittoni
    Maristella Bianconi
    Marina Scarpelli
    Raffaella Bracci
    Mario Scartozzi
    Stefano Cascinu
    Gastric Cancer, 2017, 20 : 156 - 163
  • [47] Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
    Giampieri, Riccardo
    Maccaroni, Elena
    Mandolesi, Alessandra
    Del Prete, Michela
    Andrikou, Kalliopi
    Faloppi, Luca
    Bittoni, Alessandro
    Bianconi, Maristella
    Scarpelli, Marina
    Bracci, Raffaella
    Scartozzi, Mario
    Cascinu, Stefano
    GASTRIC CANCER, 2017, 20 (01) : 156 - 163
  • [48] Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study
    Marschner, Norbert
    Arnold, Dirk
    Engel, Erik
    Hutzschenreuter, Ulrich
    Rauh, Jacqueline
    Freier, Werner
    Hartmann, Holger
    Frank, Melanie
    Jaenicke, Martina
    CLINICAL EPIDEMIOLOGY, 2015, 7 : 295 - 303
  • [49] Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
    Venook, Alan P.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Innocenti, Federico
    Fruth, Briant
    Meyerhardt, Jeffrey A.
    Schrag, Deborah
    Greene, Claire
    O'Neil, Bert H.
    Atkins, James Norman
    Berry, Scott
    Polite, Blase N.
    O'Reilly, Eileen M.
    Goldberg, Richard M.
    Hochster, Howard S.
    Schilsky, Richard L.
    Bertagnolli, Monica M.
    El-Khoueiry, Anthony B.
    Watson, Peter
    Benson, Al B., III
    Mulkerin, Daniel L.
    Mayer, Robert J.
    Blanke, Charles
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2392 - 2401
  • [50] Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
    Kabbinavar, Fairooz F.
    Hurwitz, Herbert I.
    Yi, Jing
    Sarkar, Somnath
    Rosen, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 199 - 205
12345